Mondelēz International has unveiled a new range of lower calories nougat bars coated in Cadbury chocolate, containing only 91 calories, dubbed Cadbury Delights.
The range of nougat bars, which features a soft nougat filling and caramel layer inside, comprises salted caramel, orange and caramel, and hazelnut and caramel flavors.
According to Abi Eayrs, brand manager for Cadbury Delights at Mondelēz International, consumers are increasingly looking for lower-calorie snacks where they don’t have to compromise on taste or satisfaction.
Eayrs added that the lower-calorie chocolate category is growing by over 21 percent annually and their new range of Cadbury Delights presents a huge opportunity for retailers and wholesalers to drive incremental sales.
Cadbury Delights will be sold by next month for an RRP of £1.99.


Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure
The Beauty Beneath the Expressway: A Journey from Self to Service
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty
Yes, government influences wages – but not just in the way you might think
What’s the difference between baking powder and baking soda? It’s subtle, but significant
Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 



